The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured surgically. - Pre-operative Octreotide LAR for Acromegaly
Phase 1
- Conditions
- Acromegaly, overproduction of growth hormone by (almost always) a benign pituitary tumour.
- Registration Number
- EUCTR2005-003496-20-GB
- Lead Sponsor
- Oxford Radcliffe Hospitals NHS trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Acromegaly undergoing pituitary surgery in Oxford
Macroadenoma (pituitary tumour >1cm in size on MRI)
Age 16-85
Not taking concomittant somatostatin analogue therapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Microadenoma
Previous surgery or radiotherapy
Age <16
Liver dysfunction
Renal Failure (creat >200UMOL/L)
Known Cardiac conduction disease
History of Pancreatitis
Pregnancy
Breast Feeding
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method